Researcher profile

Peiran Jiang

Peiran Jiang contributes to research discovery and scholarly infrastructure.

ResearcherAffiliation not importedOpen to collaborate

Trust snapshot

Quick read

Trust 15 - UnverifiedVerification L1Unclaimed author
3works
0followers
3topics
4close collaborators

Actions

Decide how to stay connected

Follow researcher0

Identity and collaboration

How to connect with this researcher

Claiming links this public author record to a researcher profile and unlocks direct collaboration workflows.

Log in to claim

Direct collaboration

Open a focused conversation when the fit is right

Claim this author entity first to unlock direct invitations.

Research graph

See the researcher in context

Open full explorer

Inspect adjacent work, topics, institutions and collaborators without jumping out to a separate graph page.

Building this graph slice

BZPEER is loading the nearby papers, people, topics and institutions for this page.

Published work

3 published item(s)

preprint2026arXiv

Breaking the Bottlenecks: Scalable Diffusion Models for 3D Molecular Generation

Diffusion models have emerged as a powerful class of generative models for molecular design, capable of capturing complex structural distributions and achieving high fidelity in 3D molecule generation. However, their widespread use remains constrained by long sampling trajectories, stochastic variance in the reverse process, and limited structural awareness in denoising dynamics. The Directly Denoising Diffusion Model (DDDM) mitigates these inefficiencies by replacing stochastic reverse MCMC updates with deterministic denoising step, substantially reducing inference time. Yet, the theoretical underpinnings of such deterministic updates have remained opaque. In this work, we provide a principled reinterpretation of DDDM through the lens of the Reverse Transition Kernel (RTK) framework by Huang et al. 2024, unifying deterministic and stochastic diffusion under a shared probabilistic formalism. By expressing the DDDM reverse process as an approximate kernel operator, we show that the direct denoising process implicitly optimizes a structured transport map between noisy and clean samples. This perspective elucidates why deterministic denoising achieves efficient inference. Beyond theoretical clarity, this reframing resolves several long-standing bottlenecks in molecular diffusion. The RTK view ensures numerical stability by enforcing well-conditioned reverse kernels, improves sample consistency by eliminating stochastic variance, and enables scalable and symmetry-preserving denoisers that respect SE(3) equivariance. Empirically, we demonstrate that RTK-guided deterministic denoising achieves faster convergence and higher structural fidelity than stochastic diffusion models, while preserving chemical validity across GEOM-DRUGS dataset. Code, models, and datasets are publicly available in our project repository.

preprint2020arXiv

DTF: Deep Tensor Factorization for Predicting Anticancer Drug Synergy

Motivation: Combination therapies have been widely used to treat cancers. However, it is cost- and time-consuming to experimentally screen synergistic drug pairs due to the enormous number of possible drug combinations. Thus, computational methods have become an important way to predict and prioritize synergistic drug pairs. Results: We proposed a Deep Tensor Factorization (DTF) model, which integrated a tensor factorization method and a deep neural network (DNN), to predict drug synergy. The former extracts latent features from drug synergy information while the latter constructs a binary classifier to predict the drug synergy status. Compared to the tensor-based method, the DTF model performed better in predicting drug synergy. The area under the precision-recall curve (PR AUC) was 0.57 for DTF and 0.24 for the tensor method. We also compared the DTF model with DeepSynergy and logistic regression models and found that the DTF outperformed the logistic regression model and achieved almost the same performance as DeepSynergy using several typical metrics for the classification task. Applying the DTF model to predict missing entries in our drug-cell line tensor, we identified novel synergistic drug combinations for 10 cell lines from the 5 cancer types. A literature survey showed that some of these predicted drug synergies have been identified in vivo or in vitro. Thus, the DTF model could be valuable in silico tool for prioritizing novel synergistic drug combinations.

preprint2019arXiv

Deep graph embedding for prioritizing synergistic anticancer drug combinations

Drug combinations are frequently used for the treatment of cancer patients in order to increase efficacy, decrease adverse side effects, or overcome drug resistance. Given the enormous number of drug combinations, it is cost- and time-consuming to screen all possible drug pairs experimentally. Currently, it has not been fully explored to integrate multiple networks to predict synergistic drug combinations using recently developed deep learning technologies. In this study, we proposed a Graph Convolutional Network (GCN) model to predict synergistic drug combinations in particular cancer cell lines. Specifically, the GCN method used a convolutional neural network model to do heterogeneous graph embedding, and thus solved a link prediction task. The graph in this study was a multimodal graph, which was constructed by integrating the drug-drug combination, drug-protein interaction, and protein-protein interaction networks. We found that the GCN model was able to correctly predict cell line-specific synergistic drug combinations from a large heterogonous network. The majority (30) of the 39 cell line-specific models show an area under the receiver operational characteristic curve (AUC) larger than 0.80, resulting in a mean AUC of 0.84. Moreover, we conducted an in-depth literature survey to investigate the top predicted drug combinations in specific cancer cell lines and found that many of them have been found to show synergistic antitumor activity against the same or other cancers in vitro or in vivo. Taken together, the results indicate that our study provides a promising way to better predict and optimize synergistic drug pairs in silico.